COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration by Southey, Melissa C et al.
 COMPLEXO: identifying the missing heritability of breast cancer via
next generation collaboration
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Southey, M. C., D. J. Park, T. Nguyen-Dumont, I. Campbell, E.
Thompson, A. H. Trainer, G. Chenevix-Trench, et al. 2013.
“COMPLEXO: identifying the missing heritability of breast
cancer via next generation collaboration.” Breast Cancer Research
: BCR 15 (3): 402. doi:10.1186/bcr3434.
http://dx.doi.org/10.1186/bcr3434.
Published Version doi:10.1186/bcr3434
Accessed February 19, 2015 2:56:25 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879229
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Linkage analysis, positional cloning, candidate gene 
muta tion scanning and genome-wide association study 
approaches have all contributed signiﬁ cantly to our 
understanding of the underlying genetic architecture of 
breast cancer. Taken together, these approaches have 
identiﬁ ed genetic variation that explains approximately 
30% of the overall familial risk of breast cancer, implying 
that more, and likely rarer, genetic susceptibility alleles 
remain to be discovered.
Th e application of massively parallel sequencing has 
further demonstrated the complexity of human genetic 
variation and has raised many challenges for 
computational and statistical methods for searching for 
additional breast cancer predisposition genes. Early 
ﬁ ndings are consistent with previous indications that no 
single gene is likely to account for a large proportion of 
the remaining unexplained genetic susceptibility [1,2].
Coordinated international collaboration oﬀ ers great 
potential to advance the discovery of additional breast 
cancer susceptibility genes by increasing the likelihood of 
identifying functionally relevant genetic variants in the 
same genes in multiple families. A new consortium, 
COMPLEXO (a name chosen to reﬂ ect the complexity of 
the exome), has been formed to facilitate collaborations 
between researchers actively applying massively parallel 
sequencing to understand the genetics of breast and 
ovarian cancer. Th e consortium has deﬁ ned activities 
aimed at bringing together data and resources suitable 
for exome/genome sequencing initiatives and for large 
case-control-family study resources suitable for valida-
tion of candidate susceptibility genes in which rare muta-
tions are associated with high to moderate risk of breast 
cancer. Th e aim of COMPLEXO is to bring to massively 
parallel sequencing the same power of large sample sets 
that have proven so successful in examining the role of 
common variants in cancer populations via the con sor-
tium model, such as the Breast Cancer Association 
Consortium (BCAC), the Consortium of Investigators of 
Modiﬁ ers of BRCA1/2 (CIMBA), the Ovarian Cancer 
Association Consortium (OCAC) and the Collaborative 
Oncology Gene-environment Study (COGS) [3-5]. How-
ever, sequencing studies provide additional challenges in 
terms of deﬁ ning speciﬁ c modes of collaboration given 
diﬀ erences in sequencing and targeted capture platforms, 
bioinformatics platforms, the need to integrate ongoing 
studies in many centers and socio-ethical-legal issues that 
are not as relevant to initiatives that are genotyping 
common genetic variation.
COMPLEXO invites collaboration from any researcher 
who would like to contribute to this consortium either by 
contributing data to the combined COMPLEXO data set, 
contributing resources for large-scale validation of candi-
date breast cancer predisposition genes or reﬁ ning analy-
tical and bioinformatic pipelines for massively parallel 
sequencing data ﬁ ltering and prioritization. COMPLEXO 
also has interests in the critical assessment of current 
platforms and protocols and in developing and improving © 2010 BioMed Central Ltd
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data ﬁ ltering and gene prioritization strategies to 
enhance gene discovery initiatives. Th ese approaches are 
relevant to all complex human diseases.
Interested researchers can engage with COMPLEXO 
via any local member or by contacting the corresponding 
author.
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